Morgan Stanley’s Contineum Therapeutics CTNM Stock Holding History

Morgan Stanley’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$925K	Sell	70,801 -53,485	-43%	-$717K	﹤0.01%	5182
2025 Q4	$1.42M	Buy	124,286 +31,291	+34%	+$357K	﹤0.01%	5008
2025 Q3	$1.09M	Buy	92,995 +93	+0.1%	+$750	﹤0.01%	5130
2025 Q2	$369K	Buy	92,902 +35,745	+63%	+$155K	﹤0.01%	5602
2025 Q1	$399K	Buy	57,157 +30,601	+115%	+$278K	﹤0.01%	5432
2024 Q4	$389K	Buy	26,556 +6,159	+30%	+$97.5K	﹤0.01%	5526
2024 Q3	$390K	Buy	20,397 +8,537	+72%	+$164K	﹤0.01%	5516
2024 Q2	$209K	Buy	+11,860	New	+$191K	﹤0.01%	5656

Other funds holding CTNM

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley's CTNM Position: Q1 2026 in Review

Morgan Stanley reduced its Contineum Therapeutics (CTNM) stake by 43% in Q1 2026, selling an estimated $717K and leaving 70,801 shares worth $925K. The position accounts for ﹤0.01% of the portfolio, ranked #5182.

Morgan Stanley first reported a position in CTNM in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.42M in Q4 2025. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

Morgan Stanley held 70,801 shares of Contineum Therapeutics worth $925K as of Q1 2026.
Morgan Stanley sold 53,485 Contineum Therapeutics shares in Q1 2026, an estimated $717K.
Contineum Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5182 holding.
Morgan Stanley first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 8 quarters since.
Morgan Stanley's Contineum Therapeutics position peaked at $1.42M in Q4 2025.
90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.